Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5

L. A. Anderson; A. Tavilla; H. Brenner; S. Luttmann; C. Navarro; A. T. Gavin; B. Holleczek; B. T. Johnston; M. B. Cook; F. Bannon; M. Sant; M. Hackl; N. Zielonke; W. Oberaigner; E. Van Eycken; K. Henau; Z. Valerianova; N. Dimitrova; M. Sekerija; M. Zvolský; L. Dusek; H. Storm; G. Engholm; M. Mägi; T. Aareleid; N. Malila; K. Seppä; M. Velten; X. Troussard; V. Bouvier; G. Launoy; A. V. Guizard; J. Faivre; A. M. Bouvier; P. Arveux; M. Maynadié; M. Robaszkiewicz; A. S. Woronoff; I. Baldi; A. Monnereau; B. Tretarre; N. Bossard; A. Belot; M. Colonna; F. Molinié; M. Meyer; M. J. Sanchez; S. Khan; G. Lawrence; J. Wilkinson

doi:10.1016/j.ejca.2015.07.026

Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5

L. A. Anderson^*, A. Tavilla, H. Brenner, S. Luttmann, C. Navarro, A. T. Gavin, B. Holleczek, B. T. Johnston, M. B. Cook, F. Bannon, M. Sant, M. Hackl, N. Zielonke, W. Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, M. ZvolskýL. Dusek, H. Storm, G. Engholm, M. Mägi, T. Aareleid, N. Malila, K. Seppä, M. Velten, X. Troussard, V. Bouvier, G. Launoy, A. V. Guizard, J. Faivre, A. M. Bouvier, P. Arveux, M. Maynadié, M. Robaszkiewicz, A. S. Woronoff, I. Baldi, A. Monnereau, B. Tretarre, N. Bossard, A. Belot, M. Colonna, F. Molinié, M. Meyer, M. J. Sanchez, S. Khan, G. Lawrence, J. Wilkinson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

134 Citations (Scopus)

Abstract

Background European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. Materials and methods EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised 'complete analysis' RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004 and 2005-2007 were investigated using the 'period' RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Results Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005-2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005-2007, with Central, Southern and Eastern Europe showing the greatest increases (≥9%). Conclusions Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.

Original language	English
Pages (from-to)	2144-2157
Number of pages	14
Journal	European Journal of Cancer
Volume	51
Issue number	15
Early online date	26 Sept 2015
DOIs	https://doi.org/10.1016/j.ejca.2015.07.026
Publication status	Published - 1 Oct 2015

Bibliographical note

The study was funded by the Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No20102202). The Northern Ireland Cancer Registry is supported by the Public Health Agency for N. Ireland. Dr. Michael Cook is funded by US Federal Funds. The Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No 20102202). The funding sources had no role in study design, the collection, analysis or interpretation of data, the writing of the report or the decision to submit the article for publication.

Keywords

Europe
Oesophageal
Small intestine
Stomach
Survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2015.07.026Licence: Unspecified

Cite this

Anderson, L. A., Tavilla, A., Brenner, H., Luttmann, S., Navarro, C., Gavin, A. T., Holleczek, B., Johnston, B. T., Cook, M. B., Bannon, F., Sant, M., Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., ... Wilkinson, J. (2015). Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. European Journal of Cancer, 51(15), 2144-2157. https://doi.org/10.1016/j.ejca.2015.07.026

Anderson, LA, Tavilla, A, Brenner, H, Luttmann, S, Navarro, C, Gavin, AT, Holleczek, B, Johnston, BT, Cook, MB, Bannon, F, Sant, M, Hackl, M, Zielonke, N, Oberaigner, W, Van Eycken, E, Henau, K, Valerianova, Z, Dimitrova, N, Sekerija, M, Zvolský, M, Dusek, L, Storm, H, Engholm, G, Mägi, M, Aareleid, T, Malila, N, Seppä, K, Velten, M, Troussard, X, Bouvier, V, Launoy, G, Guizard, AV, Faivre, J, Bouvier, AM, Arveux, P, Maynadié, M, Robaszkiewicz, M, Woronoff, AS, Baldi, I, Monnereau, A, Tretarre, B, Bossard, N, Belot, A, Colonna, M, Molinié, F, Meyer, M, Sanchez, MJ, Khan, S, Lawrence, G & Wilkinson, J 2015, 'Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5', European Journal of Cancer, vol. 51, no. 15, pp. 2144-2157. https://doi.org/10.1016/j.ejca.2015.07.026

@article{081b3bd69795442b9f84b702256cc273,

title = "Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5",

abstract = "Background European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. Materials and methods EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised 'complete analysis' RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004 and 2005-2007 were investigated using the 'period' RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Results Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005-2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005-2007, with Central, Southern and Eastern Europe showing the greatest increases (≥9%). Conclusions Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.",

keywords = "Europe, Oesophageal, Small intestine, Stomach, Survival",

author = "Anderson, {L. A.} and A. Tavilla and H. Brenner and S. Luttmann and C. Navarro and Gavin, {A. T.} and B. Holleczek and Johnston, {B. T.} and Cook, {M. B.} and F. Bannon and M. Sant and M. Hackl and N. Zielonke and W. Oberaigner and {Van Eycken}, E. and K. Henau and Z. Valerianova and N. Dimitrova and M. Sekerija and M. Zvolsk{\'y} and L. Dusek and H. Storm and G. Engholm and M. M{\"a}gi and T. Aareleid and N. Malila and K. Sepp{\"a} and M. Velten and X. Troussard and V. Bouvier and G. Launoy and Guizard, {A. V.} and J. Faivre and Bouvier, {A. M.} and P. Arveux and M. Maynadi{\'e} and M. Robaszkiewicz and Woronoff, {A. S.} and I. Baldi and A. Monnereau and B. Tretarre and N. Bossard and A. Belot and M. Colonna and F. Molini{\'e} and M. Meyer and Sanchez, {M. J.} and S. Khan and G. Lawrence and J. Wilkinson",

note = "The study was funded by the Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No20102202). The Northern Ireland Cancer Registry is supported by the Public Health Agency for N. Ireland. Dr. Michael Cook is funded by US Federal Funds. The Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No 20102202). The funding sources had no role in study design, the collection, analysis or interpretation of data, the writing of the report or the decision to submit the article for publication.",

year = "2015",

month = oct,

day = "1",

doi = "10.1016/j.ejca.2015.07.026",

language = "English",

volume = "51",

pages = "2144--2157",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER APPL SCI PUBL LTD",

number = "15",

}

TY - JOUR

T1 - Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007

T2 - Results from EUROCARE-5

AU - Anderson, L. A.

AU - Tavilla, A.

AU - Brenner, H.

AU - Luttmann, S.

AU - Navarro, C.

AU - Gavin, A. T.

AU - Holleczek, B.

AU - Johnston, B. T.

AU - Cook, M. B.

AU - Bannon, F.

AU - Sant, M.

AU - Hackl, M.

AU - Zielonke, N.

AU - Oberaigner, W.

AU - Van Eycken, E.

AU - Henau, K.

AU - Valerianova, Z.

AU - Dimitrova, N.

AU - Sekerija, M.

AU - Zvolský, M.

AU - Dusek, L.

AU - Storm, H.

AU - Engholm, G.

AU - Mägi, M.

AU - Aareleid, T.

AU - Malila, N.

AU - Seppä, K.

AU - Velten, M.

AU - Troussard, X.

AU - Bouvier, V.

AU - Launoy, G.

AU - Guizard, A. V.

AU - Faivre, J.

AU - Bouvier, A. M.

AU - Arveux, P.

AU - Maynadié, M.

AU - Robaszkiewicz, M.

AU - Woronoff, A. S.

AU - Baldi, I.

AU - Monnereau, A.

AU - Tretarre, B.

AU - Bossard, N.

AU - Belot, A.

AU - Colonna, M.

AU - Molinié, F.

AU - Meyer, M.

AU - Sanchez, M. J.

AU - Khan, S.

AU - Lawrence, G.

AU - Wilkinson, J.

N1 - The study was funded by the Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No20102202). The Northern Ireland Cancer Registry is supported by the Public Health Agency for N. Ireland. Dr. Michael Cook is funded by US Federal Funds. The Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No 20102202). The funding sources had no role in study design, the collection, analysis or interpretation of data, the writing of the report or the decision to submit the article for publication.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. Materials and methods EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised 'complete analysis' RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004 and 2005-2007 were investigated using the 'period' RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Results Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005-2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005-2007, with Central, Southern and Eastern Europe showing the greatest increases (≥9%). Conclusions Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.

AB - Background European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. Materials and methods EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised 'complete analysis' RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004 and 2005-2007 were investigated using the 'period' RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Results Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005-2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005-2007, with Central, Southern and Eastern Europe showing the greatest increases (≥9%). Conclusions Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.

KW - Europe

KW - Oesophageal

KW - Small intestine

KW - Stomach

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84942474470&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.07.026

DO - 10.1016/j.ejca.2015.07.026

M3 - Article

SN - 0959-8049

VL - 51

SP - 2144

EP - 2157

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 15

ER -

Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this